EUCTR2004-001417-33-IT进行中（未招募）不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy
AMGE0 个研究点开始时间: 2005年7月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-GBAmgen Inc400
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-SEAmgen Inc400
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingEUCTR2004-001417-33-HUAmgen Inc400
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-DKAmgen Inc400
进行中（未招募）
1 期
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-CZAmgen Inc400